Multiple Myeloma: ASCO Tumor Boards

This is a case-based activity that includes discussion of two patients:

  1. A 64-year-old woman with relapsed IgG kappa myeloma presents to the clinic. She originally presented with standard risk disease and was treated with RVd induction therapy. She achieved a VGPR. Treatment continued with autologous stem cell transplant with achievement of CR, following by lenalidomide maintenance for 3 years.
  2. A 71-year-old man presents to clinic with lytic lesions in his axial and appendicular skeleton. He was originally diagnosed with IgA kappa multiple myeloma. FISH showed del (17p), a high-risk feature.

Learning Objectives

  • Differentiate standard staging and prognostic markers
  • Select a therapy based on goals and options
  • Describe host/disease factors that guide therapeutic options in first relapse
  • Assess available treatment regimens for relapsed/refractory patients
  • Evaluate clinical trial results of potential new regimens

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

This course expires on May 17, 2020. Participants must complete all necessary course components by this date. This course is also available as part of the 2017 ASCO Tumor Boards bundle.